Basic Information
| LncRNA/CircRNA Name | lncRNA-SRLR |
| Synonyms | LNCSRLR, lncRNA-SRLR |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | renal cell carcinoma |
| ICD-0-3 | C64.9 |
| Methods | Microarray, RIP, ChIP, RNA pull-down assay etc. |
| Sample | RCC tissues, cell lines (786-O, ACHN, 769P, HEK-293T, Caki-2 etc.) |
| Expression Pattern | up-regulated |
| Function Description | Herein, we identified a long non-coding RNA referred to as lncRNA-SRLR (sorafenib resistance-associated lncRNA in RCC) that is upregulated in intrinsically sorafenib-resistant RCCs. lncRNA-SRLR knockdown sensitized nonresponsive RCC cells to sorafenib treatment, whereas the overexpression of lncRNA-SRLR conferred sorafenib resistance to responsive RCC cells. Mechanistically, lncRNA-SRLR directly binds to NF-kB and promotes IL-6 transcription, leading to the activation of STAT3 and the development of sorafenib tolerance. A STAT3 inhibitor and IL-6-receptor antagonist both restored the response to sorafenib treatment. |
| Pubmed ID | 27841868 |
| Year | 2016 |
| Title | Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. |
External Links
| Links for lncRNA-SRLR | GenBank HGNC NONCODE |
| Links for renal cell carcinoma | OMIM COSMIC |